Eladi Churna and Draksharishta Improve Clinical Features and Functional Status of Lungs in Patients With Stable Chronic Bronchitis

Abstract

Introduction

Chronic bronchitis (CB) is a common pulmonary disease that is a significant cause of morbidity and mortality worldwide, and better healthcare approaches are still needed. As such, Ayurvedic therapies must be explored to manage CB. The purpose of this trial was to examine and validate the clinical efficacy and safety of Eladi Churna and Draksharishta for the management of stable CB.

Methods

A total of 130 participants with stable CB were registered in this study, out of which 110 participants completed the trial. Eladi Churna was given orally in a dose of 3 g thrice a day with honey after food. Draksharishta was administered orally in a dose of 20 ml twice daily for 84 days with an equal quantity of water after food.

Results

The effectiveness and safety of Ayurvedic therapy were assessed using clinical characteristics, the forced expiratory volume in 1 s score and the peak expiratory flow rate, the Leicester cough questionnaire score, the St George's respiratory questionnaire score, and hematological and biochemical investigations which were measured at the initiation of the trial and after completion of the trial. Clinical characteristics, forced expiratory volume in 1 s score, peak expiratory flow rate, Leicester cough questionnaire score, and St George's respiratory questionnaire scores were improved significantly with these trial medicines. The results showed that the participants who consumed these medicines had no adverse side effects.

Conclusions

Eladi Churna and Draksharishta is beneficial and safe in long-term use to improve the clinical features and functional status of the lungs of patients with CB.